The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Mega Mergers
Stock Buybacks
Stock Buybacks
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
UTHR Buyback image

United Therapeutics Corporation Buyback

OLI recorded this information on 3/25/2024

Company: United Therapeutics Corporation
Buyback: UTHR buyback
$Amount Authorized: $1,000,000,000
Buyback Details: United Therapeutics Corporation (NASDAQ:,b,UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics' common stock. This program builds on United Therapeutics' planned $400 million paydown of its revolving credit facility in 2024, of which $100 million was paid down during the first quarter of 2024. To enact the program, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A. (Citi) to repurchase $1 billion of the company's common stock.

United Therapeutics is a biotechnology company. Co. markets and sells four commercial therapies in the U.S. to treat pulmonary arterial hypertension: Tyvaso® (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin® (treprostinil) Injection (Remodulin); Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, which is approved for treatment of high-risk neuroblastoma, and the Remunity® Pump for Remodulin.

UTHR SEC Filing Email Alerts Service

Open the UTHR Page at The Online Investor »

UTHR — Key Stats (updated 18 hours, 2 minutes ago)
Company Name:  United Therapeutics Corp
Stock buyback:  UTHR buyback
Website:  www.unither.com
Sector:  Biotechnology
Number of ETFs Holding UTHR:  83
Total Market Value Held by ETFs:  $2.00B
Total Market Capitalization:  $11.06B
% of Market Cap. Held by ETFs:  18.10%
 

Open the UTHR Page at The Online Investor (in a new window) »
April 18, 2024  •  4:35 AM Eastern
UTHR — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree UTHR Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Strong Buy (3.50 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
UTHR Stock Forecast

 Based on Zacks ABR data;
powered by Xignite

UTHR Buyback | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.